{
    "organizations": [],
    "uuid": "54b4023daf8b0732acba3dd1284d6d490553d6d6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-esperion-says-phase-3-long-term-sa/brief-esperion-says-phase-3-long-term-safety-study-of-bempedoic-acid-met-primary-endpoint-idUSASC09YYM",
    "ord_in_thread": 0,
    "title": "BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2, 2018 / 11:53 AM / Updated 7 minutes ago BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint Reuters Staff\nMay 2 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID\n* ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY IN LARGEST AND LONGEST DURATION STUDY\n* ESPERION - PATIENTS TREATED WITH BEMPEDOIC ACID ALSO ACHIEVED A SIGNIFICANT REDUCTION OF 22 PERCENT IN HIGH-SENSITIVITY C-REACTIVE PROTEIN Source text for Eikon: Further company coverage:",
    "published": "2018-05-02T14:53:00.000+03:00",
    "crawled": "2018-05-02T15:10:36.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "updated",
        "minute",
        "ago",
        "say",
        "phase",
        "safety",
        "study",
        "bempedoic",
        "acid",
        "met",
        "primary",
        "endpoint",
        "reuters",
        "staff",
        "may",
        "reuters",
        "esperion",
        "therapeutic",
        "inc",
        "esperion",
        "announces",
        "positive",
        "result",
        "pivotal",
        "phase",
        "safety",
        "study",
        "bempedoic",
        "acid",
        "esperion",
        "therapeutic",
        "inc",
        "study",
        "met",
        "primary",
        "endpoint",
        "safety",
        "tolerability",
        "largest",
        "longest",
        "duration",
        "study",
        "esperion",
        "patient",
        "treated",
        "bempedoic",
        "acid",
        "also",
        "achieved",
        "significant",
        "reduction",
        "percent",
        "protein",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}